鼻咽癌IMRT后舌下神经放射损伤预测模型的建立与验证
该研究回顾性分析423例接受IMRT的鼻咽癌患者,随机按3:2分为训练集256例和测试集167例,建立含舌下神经管受累、同步化疗、D1cc和aV75的竞争风险模型并绘制列线图,训练集和测试集C指数分别为0.726和0.691。
要点
- 中位随访102个月,3、5、8年舌下神经放射损伤累积发生率分别为2.1%、5.4%、10.5%。
- D1cc和aV75是最具预测价值的剂量学变量,D1cc对应8年5%发生率的耐受剂量TD5/8为77.3 Gy(EQD2)。
- aV75与损伤风险的限制性立方样条提示体积阈值为0.81 cm3。
核心结论
- 研究识别了最关键的剂量学预测因子,有望成为舌下神经可行的剂量约束。
- 结合剂量学和临床预测因子,首次提出并验证了量化舌下神经放射损伤风险的列线图模型,有助于识别高危患者和早期干预。
- 需要进一步的多中心研究来验证或补充本研究发现。
研究设计与样本
- 回顾性分析423例接受IMRT为基础治疗的鼻咽癌患者,随机按3:2分为训练集256例和测试集167例。
- 采用惩罚回归和机器学习筛选剂量学变量并计算AUC,采用竞争风险分析筛选临床变量。
- 建立含临床和剂量学变量的竞争风险模型,并生成列线图可视化预测舌下神经放射损伤发生率。
主要发现
- 中位随访102个月(IQR:89.5至112.9个月),3、5、8年舌下神经放射损伤累积发生率分别为2.1%、5.4%、10.5%。
- D1cc和aV75是最具预测价值的剂量学变量。
- D1cc绘制的剂量效应曲线提示8年内发生舌下神经放射损伤概率5%的耐受剂量TD5/8为77.3 Gy(EQD2)。
- aV75与舌下神经放射损伤的限制性立方样条提示体积阈值为0.81 cm3。
- 含舌下神经管受累、同步化疗、D1cc和aV75的竞争风险模型,训练集C指数为0.726,测试集C指数为0.691。
关键数值与推荐
- 列线图定义的高危组在训练集和测试集中舌下神经放射损伤发生率更高。
- D1cc对应8年5%发生率的耐受剂量TD5/8为77.3 Gy(EQD2)。
- aV75与舌下神经放射损伤相关的体积阈值为0.81 cm3。
- 竞争风险模型训练集C指数0.726,测试集C指数0.691。
临床怎么用
- D1cc和aV75可作为舌下神经的剂量约束参考。
- 列线图模型可量化舌下神经放射损伤风险,帮助识别高危患者。
- 高危患者可考虑早期干预。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To establish predictive models for radiation-induced hypoglossal neuropathy (RIHN) in patients with nasopharyngeal carcinoma (NPC) after intensity-modulated radiotherapy (IMRT). MATERIALS AND METHODS: Data from 423 NPC patients receiving IMRT-based treatment were retrospectively reviewed. They were randomly (3:2) divided into a training set (n = 256) and a testing set (n = 167). Dosimetric variables were selected by penalized regression and machine learning, with area under the receiver operating curve (AUC) calculated. Clinical variables were selected by the competitive risk analysis. A competitive risk model including clinical and dosimetric variables was performed, and a nomogram was generated as a visualization of the model to predict the incidence of RIHN. RESULTS: During a median follow-up of 102 months (IQR: 89.5 to 112.9 months), the cumulative incidence of RIHN at 3, 5, and 8 years were 2.1 %, 5.4 %, and 10.5 %, respectively. D1cc and aV75 were the most predictive dosimetric variables. The dose-effect curve plotted with D1cc indicated the tolerance dose for a 5 % probability of developing RIHN in 8 years (TD5/8) was 77.3 Gy (EQD2). The restricted cubic spline between aV75 and RIHN indicated a volume threshold of 0.81 cm3. A competitive risk model including hypoglossal canal involvement, concurrent chemotherapy, D1cc, and aV75 was established, with the C-index of the training set and testing set being 0.726 and 0.691, respectively. The nomogram-defined high-risk group had the higher RIHN incidences in the training and testing sets. CONCLUSIONS: This study identified the most critical dosimetric predictors, which is expected to become a feasible dose constraint for hypoglossal nerves in radiation plan. Combining dosimetric and clinical predictors, we further proposed and validated the first nomogram model to quantify the risk of RIHN, contributing to identifying high-risk patients and early intervention. Further multicenter studies are needed to validate or complement our findings.
引用
- Wang Z, Li L, Wu Y, et al. Development and validation of Prediction models for radiation-induced hypoglossal neuropathy in patients with nasopharyngeal carcinoma. Radiother Oncol. 2025. PMID: 40209855. doi:10.1016/j.radonc.2025.110887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。